Flemming Ørnskov
Flemming Ørnskov | |
|---|---|
| Born | 1957 or 1958 (age 65–66)[1] |
| Nationality | Danish |
| Alma mater | University of Copenhagen INSEAD Harvard University |
| Occupation(s) | CEO, Shire plc |
Flemming Ørnskov (born 1957/58) is a Danish businessman. He is the chief executive officer (CEO) of Galderma[2] and has previously been the CEO of Shire plc, a FTSE 100 speciality biopharmaceutical company since 30 April 2013, succeeding Angus Russell.[3] He previously worked for Bayer, Bausch & Lomb and Novartis.[2]
Ørnskov received his MD from the University of Copenhagen, followed by an MBA from INSEAD, and a Master of Public Health (MPH) from Harvard University.[1]
References
- ^ a b c "Executive Profile: Flemming Ornskov". Bloomberg. Retrieved 4 September 2017.
- ^ a b Liu, Angus (October 8, 2019). "Ex-Shire CEO Flemming Ornskov emerges as Galderma CEO after $10B Nestlé spinout". Fiercepharma.
- ^ "Shire chief finds right prescription for growth". The Telegraph. Retrieved 20 March 2014.
  | This Danish biographical article is a stub. You can help Wikipedia by expanding it. |
 | This business-related biographical article is a stub. You can help Wikipedia by expanding it. |